New Court Ruling Heightens Uncertainty Surrounding Canada's Drug Pricing Reform
Pharma & Healthcare / Canada / Tue 08 Mar, 2022
Key View
- Two out of three key provisions in Canada’s drug pricing reform have been found unconstitutional by Quebec’s Court of Appeal and are expected to be struck from implementation in July 2022.
- The upheld provision will alter the country’s reference price basket and poses significant downside risk to innovative drugmakers when enforced.